PROFESSIONAL POLICY TRAINING · CHINA
Governing Price Risk in China’s Shortage-Medicine Market: Supply Security, Listing Decisions, Payment Incentives, and Regulatory Controls
China’s framework is not a conventional price cap. It preserves market pricing and direct listing for medicines whose supply is clinically fragile, while moving disclosure, comparison, accountability, and post-listing monitoring earlier in the decision chain. Sound analysis must connect four questions without collapsing them: Is supply clinically constrained? How is the price listed? How is use paid? What evidence can trigger regulatory review?
Primary sources
- NHSA: Operational Guidance on Price-Risk Management for Shortage Medicines, NHSA Office Document No. 30 [2024] (Chinese)
- NHSA: Official policy interpretation of the Operational Guidance (Chinese)
- General Office of the State Council: Opinion on securing supply and stabilising prices of shortage medicines (Chinese)
- NHSA: Notice on Healthcare Security Fund Supervision in 2026 (Chinese)
- NHSA: Launch of the 2026 national healthcare security fund flight inspections (Chinese)
1. The analytical error to avoid: treating one price as four decisions
| Layer | Decision | Principal actors | What it does not prove |
|---|---|---|---|
| Shortage designation and supply | Whether the medicine is clinically necessary, non-substitutable or not fully substitutable, and supply-constrained | Inter-agency coordination mechanisms, health authorities, regulators, providers | Designation does not make every proposed price reasonable |
| Price and platform listing | How an independently set price is disclosed, compared, labelled, listed, and monitored | Marketing authorization holder, provincial NHSA authority, procurement platform | A listed price is neither a mandatory hospital purchase nor necessarily the transaction price |
| Procurement and clinical use | Inventory thresholds, therapeutic substitution, emergency filing, and rational use | Pharmacy, procurement, medical affairs, clinicians | Clinical urgency does not erase platform filing and evidence requirements |
| Insurance payment and supervision | Whether expenditure is covered, how the provider is settled, and whether a claim is valid | Pooling-region purchaser, provider insurance office, finance, clinicians | Formulary inclusion does not mean full reimbursement; price risk is not automatically fraud |
2. How the framework allocates accountability
A manufacturer seeking a price increase through the shortage-medicine channel must disclose production and supply, price history, therapeutically comparable products, price build-up, distribution relationships, and potentially competition-restricting contractual terms. The first province accepting the increase becomes the coordinating jurisdiction for document review, price and cost investigation, remediation, and information sharing. The production province and high-purchase provinces support that work.
| Listing route | Decision logic | Platform treatment | Provider implication |
|---|---|---|---|
| Direct-pass listing | A national-list or emergency product with complete disclosure that meets a specified cost, comparison, increase, low-daily-cost, or audit condition | The independently proposed price is listed directly | Hospital formulary admission, demand forecasting, and transaction-price control still apply |
| Substitution-warning listing | The direct-pass route is unavailable and a domestic product of the same therapeutic use exists | Direct listing with yellow or red risk labelling and substitution prompts | Selection should be explainable through clinical difference, supply access, and price risk |
| Conditional listing | The direct-pass route is unavailable and no domestic product of the same therapeutic use exists | Listing is accepted against public commitments on price, supply, integrity, and consequences | “No substitute” requires continued monitoring; it is not an unlimited procurement mandate |
The numerical tests in the Guidance—such as 2×, 3×, 50%, and 1.8×—use different denominators, windows, and legal functions. They are screening and classification rules, not a safe-harbour pricing formula.
3. Clinical operations: the policy ultimately governs treatment continuity
Emergency, paediatric, major-disease, public-health, and special-population medicines may combine low volume, few suppliers, and narrow substitution windows. Pharmacy must therefore integrate days of stock, open orders, consumption, supplier response, and therapeutic alternatives. Clinicians establish whether interruption or substitution is safe. Procurement selects the platform route. Insurance and finance teams determine how expenditure enters patient billing and payer settlement.
| Clinical event | Settlement context | Regulatory detection | Provider action |
|---|---|---|---|
| Emergency stock falls below threshold and no active listing exists | Under FFS, the medicine may appear as a claim line; coverage still depends on benefit rules | Comparison of off-platform purchase records, filing records, and filing date | Confirm shortage and necessity, approve emergency purchase, file within seven working days |
| A red-labelled product coexists with a lower-risk therapeutic alternative | Under DRG/DIP, the medicine generally becomes a case cost, creating pressure to underuse or shift cost | Procurement mix, self-pay rate, disease-level cost, and clinical rationale | Pharmacist substitution review and patient-specific documentation for exceptions |
| A long-stay patient requires stable access to an easily short medicine | Per-diem or other fixed settlement may not increase when medicine cost rises | Drug intensity, external-purchase instructions, interruptions, and quality outcomes | Protect necessary treatment through exception review and patient-burden monitoring |
| Supply normalises but high-price exceptional purchasing continues | Any payment method may retain unjustified cost or fund expenditure | Time-series mismatch across price, delivery, inventory, and alternative availability | Set expiry and reassessment points for every procurement exception |
4. Payment behaviour: the same increase creates different incentives
Fee-for-service (FFS)
Where a medicine appears as an itemised charge, price and volume transmit more visibly into patient and fund expenditure. Risks include selection without adequate clinical grounds, excessive prescribing, substitution in claims, and billing outside coverage. The proper control is not “always buy the cheapest”; it is a documented decision combining indication, substitutability, supply continuity, and local benefit rules.
DRG and DIP prospective payment
A higher listed price does not automatically increase a DRG weight or rate, a DIP score, or the local point value. It first raises case cost. Poorly designed management can then encourage under-treatment, external self-pay purchase, fragmented admissions, or risk selection. Legitimate mismatch should be handled through locally available exceptional-case review, carve-outs, or purchaser-provider negotiation—not by changing clinical facts or shifting necessary cost.
Per-diem and other fixed payment
A relatively fixed daily payment makes an input-price increase compete with other services inside the day. Long-stay psychiatry, rehabilitation, nursing, or similar settings require explicit safeguards against delayed dosing, unjustified dose reduction, external purchase, and avoidable transfer. Clinical quality indicators should counterbalance cost-only targets.
5. Regulatory boundary: price governance is not a fund flight inspection
Price-risk governance is not healthcare security fund inspection and cannot replace it. Price governance examines manufacturer disclosure, listing prices, delivery, procurement signals, and commitments through monitoring, warning, inquiry, interview, credit evaluation, and inter-agency referral. Fund supervision examines whether providers and other regulated actors used and claimed healthcare security funds lawfully. A suspicious listing or purchase may generate a lead, but fraud cannot be inferred without examining claims, services, agreements, evidence, and intent.
China’s 2026 programme integrates annual, thematic, and targeted (“acupuncture-point”) flight inspections. Annual inspections prioritise high fund risk, abnormal admission or payment indicators, weak remediation, and concentrated leads. Thematic inspections address prominent problems; targeted inspections use data anomalies, complaints, and unusually high self-pay rates. Drug traceability codes support investigations into recycled medicines, claim substitution, card-only transactions, and excessive dispensing; they do not by themselves prove an unlawful listed price.
6. Eight fictional training cases
All cases are fictional and do not characterize any real organization.
Case 1 — Emergency procurement was filed on the tenth working day
Clinical facts: A non-substitutable rescue medicine was unavailable on-platform.
Settlement rule: Temporary procurement can be used, but hospital filing is due within seven working days.
Regulatory characterization: Necessity does not cure the procedural defect; late filing is a lead, not automatic fraud.
Internal-control remediation: Generate a filing deadline from every emergency approval and assign joint ownership.
Case 2 — A red-labelled product was justified only as “department preference”
Clinical facts: A lower-risk same-use option existed; no contraindication or failed substitution was recorded.
Settlement rule: DRG payment does not remove rational-use duties or add payment for the higher input cost.
Regulatory characterization: Weak necessity evidence can trigger procurement and fund-use review, but individual characterization still requires facts.
Internal-control remediation: Require pharmacist review and structured exception reasons.
Case 3 — A hospital shifted a necessary inpatient medicine to out-of-pocket purchase
Clinical facts: An inpatient was directed to obtain a clinically necessary medicine externally.
Settlement rule: DIP cost pressure does not justify transferring necessary treatment cost.
Regulatory characterization: Abnormal self-pay, disease cost, and order data may create a targeted-inspection lead.
Internal-control remediation: Remove hard case-cost caps and use legitimate payment exceptions.
Case 4 — A conditionally listed supplier repeatedly failed to deliver
Clinical facts: Falling order response threatened treatment continuity.
Settlement rule: Conditional listing includes supply commitments; orders are not deliveries.
Regulatory characterization: Platform delivery data can test the commitment; fund claims remain a separate inquiry.
Internal-control remediation: Review supplier response, delivery, and shortage incidents monthly.
Case 5 — Exceptional high-price purchasing continued after supply recovered
Clinical facts: Alternatives returned, but the temporary route remained standard.
Settlement rule: No payment model validates an exception after its factual basis expires.
Regulatory characterization: Price, stock, and procurement time series form an audit lead.
Internal-control remediation: Give every exception an expiry date and mandatory reassessment.
Case 6 — A manufacturer treated one threshold as a disclosure exemption
Clinical facts: Supply was stable while the proposed price rose materially.
Settlement rule: Thresholds classify risk; they do not remove disclosure and fair-pricing responsibility.
Regulatory characterization: Incomplete disclosure can itself require correction; no single test is a blanket safe harbour.
Internal-control remediation: Maintain an evidence-indexed disclosure file with finance-business reconciliation.
Case 7 — A per-diem ward reduced required dosing after a price increase
Clinical facts: The order change lacked a clinical basis and outcomes deteriorated.
Settlement rule: Fixed daily payment does not authorize medically necessary service reduction.
Regulatory characterization: Orders, administration records, outcomes, and cost directives may establish a cost-driven pathway.
Internal-control remediation: Subject high-risk dose reductions to pharmacist and quality review.
Case 8 — A traceability-code anomaly was labelled “illegal pricing”
Clinical facts: The same code appeared in anomalous transactions across institutions.
Settlement rule: Traceability primarily supports authenticity, flow, and fund-use verification.
Regulatory characterization: It may suggest recycling, substitution, or false billing, but does not alone prove a pricing offence.
Internal-control remediation: Separate product-flow, claim, and procurement-price investigations.
7. Three lines of defence
- System rules: Integrate inventory thresholds, platform labels, filing deadlines, exception expiry, and payment attributes in one workflow.
- Data self-portrait: Track price, quantity, delivery, stock days, substitution, self-pay, and disease-level cost by generic medicine; return anomalies to clinical review.
- Accountability: Pharmacy owns substitutability, procurement owns platform and contract evidence, the insurance office owns settlement, finance owns payment reconciliation, clinicians own necessity, and audit tests the chain.
8. Assessment
- Does shortage-list inclusion make a proposed price reasonable by definition?No. It defines scope and supply priority, not price legitimacy.
- What does the first-increase province coordinate?Disclosure review, price and cost investigation, remediation, and information sharing.
- Which route generally applies when a same-use domestic product exists but direct-pass criteria do not apply?Substitution-warning listing.
- When must a hospital file qualifying temporary procurement?Within seven working days after procurement.
- Can a listed price determine the insurance payment standard?No; payment requires a separate rule.
- Does a medicine price increase automatically raise DRG/DIP payment?No; it usually first raises provider case cost.
- What evidence supports an exception to a red warning?Clinical necessity, non-substitutability, availability, and approval evidence.
- What can trigger a targeted 2026 inspection?Data anomalies, complaints, or an unusually high self-pay rate.
- Does a traceability anomaly alone prove unlawful pricing?No; the evidence chain and regulatory object differ.
- What is the four-step case method?Clinical facts → settlement rule → regulatory characterization → internal-control remediation.
FAQ
Does a higher platform-listed price automatically raise the insurance payment standard?
No. Platform listing belongs to price and procurement governance. Benefit coverage, payment standards, patient cost sharing, and DRG/DIP settlement are separate decisions governed by national and pooling-region rules.
Is a red-flagged medicine prohibited from purchase?
Not categorically. A red flag tells public providers to prioritise non-red alternatives of the same therapeutic use. A clinically necessary exception should therefore document substitutability, availability, patient-specific risk, and approval.
May a hospital procure first during a genuine shortage and document later?
The Guidance permits qualifying temporary record-filed procurement when no active platform listing exists and the medicine is clinically necessary. The hospital must complete platform filing within seven working days after procurement.
Will purchasing an expensive shortage medicine automatically create a 2026 flight-inspection violation?
No. Price-risk controls and fund-use inspections have different legal objects and evidence chains. They can intersect through claims, patient self-pay, procurement records, traceability codes, or complaints, but characterization still requires separate verification.
What is the most important hospital control?
A multidisciplinary exception ledger that links inventory alerts, clinical substitution review, platform risk labels, price changes, approval, dispensing, patient use, and the final settlement route.